Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

R. Bishop, Michael; Dickinson, Michael; Purtill, Duncan; Barba, Pere; Santoro, Armando; Hamad, Nada; Kato, Koji; Sureda, Anna; Greil, Richard; Thieblemont, Catherine; Morschhauser, Franck; Janz, Martin; W. Flinn, Ian; Rabitsch, Werner; Kwong, Yok‐Lam; José Kersten, Marie; C. Minnema, Monique; Holte, Harald; Hian Li Chan, Esther; Martínez‐López, Joaquín; Müller, Antonia; T. Maziarz, Richard; P. McGuirk, Joseph; Bachy, Emmanuel; Le Gouill, Steven; Dreyling, Martin; Harigae, Hideo; A. Bond, David; Andreadis, Charalambos; A. McSweeney, Peter; A. Kharfan‐Dabaja, Mohamed; Newsome, Simon; Degtyarev, Evgeny; Awasthi, Rakesh; del Corral, Christopher; Andreola, Giovanna; Masood, Aisha; J. Schuster, Stephen; Jäger, Ulrich; Borchmann, Peter; R. Westin, Jason

doi:10.1056/nejmoa2116596

Public

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Published in New England Journal of Medicine • Dec 14, 2021

Authors:

Michael R. Bishop

Michael Dickinson

Duncan Purtill

Abstract

BACKGROUND: Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two trea...

Subject

Aggressive lymphoma

Line (geometry)

Standard of care

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!